These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Herpes zoster and postherpetic neuralgia: advantages of the vaccination]. Cañada JL Rev Esp Quimioter; 2009 Nov; 22 Suppl 1():19-21. PubMed ID: 20084344 [No Abstract] [Full Text] [Related]
3. [Study tests Varicella-Zoster vaccine for over 60-years-old persons. Protection from Herpes zoster and postherpetic neuralgia]. MMW Fortschr Med; 2006; Spec no.1():14-5. PubMed ID: 16872127 [No Abstract] [Full Text] [Related]
4. Prevention strategies for herpes zoster and post-herpetic neuralgia. Levin MJ; Gershon AA; Dworkin RH; Brisson M; Stanberry L J Clin Virol; 2010 May; 48 Suppl 1(Suppl 1):S14-9. PubMed ID: 20510262 [TBL] [Abstract][Full Text] [Related]
5. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine. Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400 [TBL] [Abstract][Full Text] [Related]
6. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Sanford M; Keating GM Drugs Aging; 2010 Feb; 27(2):159-76. PubMed ID: 20104941 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Hornberger J; Robertus K Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357 [TBL] [Abstract][Full Text] [Related]
8. What are the new vaccination recommendations for herpes zoster? Mospan CM; Colvin N JAAPA; 2018 Oct; 31(10):14-15. PubMed ID: 30252758 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of herpes zoster vaccination in an older United Kingdom population. Walker JL; Andrews NJ; Amirthalingam G; Forbes H; Langan SM; Thomas SL Vaccine; 2018 Apr; 36(17):2371-2377. PubMed ID: 29555217 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study. Amirthalingam G; Andrews N; Keel P; Mullett D; Correa A; de Lusignan S; Ramsay M Lancet Public Health; 2018 Feb; 3(2):e82-e90. PubMed ID: 29276017 [TBL] [Abstract][Full Text] [Related]
15. Zostavax : a subcutaneous vaccine for the prevention of herpes zoster. Doan HQ; Ung B; Ramirez-Fort MK; Khan F; Tyring SK Expert Opin Biol Ther; 2013 Oct; 13(10):1467-77. PubMed ID: 23984934 [TBL] [Abstract][Full Text] [Related]
18. [Active immunoprophylaxis to reduce clinical impact of Herpes Zoster and its complications]. Marino MG; Bagnato B; Torella I; Franco E Ig Sanita Pubbl; 2009; 65(3):299-311. PubMed ID: 19629155 [TBL] [Abstract][Full Text] [Related]
19. [Two U.S. experts discuss the consequences of the "Shingles Prevention Study". Is senior vaccination worthwhile in the practice?]. MMW Fortschr Med; 2006; Spec no.1():16. PubMed ID: 16872128 [No Abstract] [Full Text] [Related]
20. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Rothberg MB; Virapongse A; Smith KJ Clin Infect Dis; 2007 May; 44(10):1280-8. PubMed ID: 17443464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]